Targeted Oncology
Advertisement
Articles by Targeted Oncology
Dr Mark Pegram and Dr Julie Gralow discuss treatment options in relapsed/refractory HER2+ metastatic breast cancer.
Key opinion leaders discuss the evolving treatment paradigm for relapsed/refractory gastrointestinal stromal tumors, and provide an overview of supplemental data presented at the ASCO (American Society of Clinical Oncology) 2020 Annual Meeting.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Savolitinib Plus Osimertinib Improves PFS, OS in MET-Driven NSCLC
2
T-DXd Improves PFS vs Standard of Care in First-Line HER2-Mutant NSCLC
3
FDA Grants Fast Track Designation to Piktor in Endometrial Cancer
4
FDA Grants Type C Meeting for OST-HER2 OS Data in Osteosarcoma
5